clinical trial · NCT06411379
Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis SuppurativaSonelokimabPlacebo
brief summary
This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa. Participants will be randomized 2:1 to either sonelokimab or matching placebo up to Week 16.
started
May 14, 2024
primary completion
Aug 14, 2025
completion
May 20, 2026
last updated
Jun 8, 2026
official title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol